While this sounds like a healthcare version of the Tom Cruise sci-fi film Minority Report, it could soon be a reality thanks to a new collaboration taking place in the north-west of England.

The next generation of the industry-proven Agilent MSD — the most popular GC/MS of all time. The 5977A MSD includes a new, highly sensitive Extractor Ion Source for higher Signal-to-Noise (SNR ...

BRONX, N.Y., Feb. 7, 2025 /PRNewswire/ -- Centers Health Care, the largest and most complete post-acute health care continuum in the Northeast that touches one million lives each year with 45 ...

managing director of MSD Ireland Human Health. The company currently operates five large-scale pharma manufacturing, research, and development sites across the country – in Ballydine ...

The 30-second spot for Brown University Health, formerly Lifespan, will air regionally, and everyone in it is an actual ...

BRONX, N.Y., Feb. 7, 2025 /PRNewswire/ -- Centers Health Care, the largest and most complete post-acute health care continuum in the Northeast that touches one million lives each year with 45 skilled ...

Federal health workers are expressing fear and alarm after a website called “DEI Watch List” published the photos, names and public information of a number of workers across health agencies ...

Jan. 22, 2025 — A new national survey found that while many Americans use a device to monitor their heart, few share that data with their ... Researchers Track Sharp Increase in Diagnoses for ...

When you imagine your retirement journey, you likely picture trips to the beach, leisurely days with the grandkids and lots of time for hobbies. A lengthy stay in a nursing home probably isn’t ...

Jan. 15, 2025 — In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive ...

Kennedy Jr. cleared a key hurdle Tuesday after a Senate panel voted to advance his nomination to be health and human services ... That included from Protect Our Care, a group attempting to stop ...

The 80-patient placebo-controlled randomized Phase 2 study will evaluate the efficacy of opaganib in combination with Bayer's darolutamide in men with metastatic castrate-resistant prostate cancer ...